JPM Research Update — September 15, 2026
Updated Thesis
JPMorgan Chase is a diversified global bank spanning consumer banking, cards, payments, commercial banking, investment banking, markets, treasury services, and asset and wealth management, with an unusually high-quality franchise supported by funding scale, distribution, leading market positions and cross-selling across 86.6 million U.S. consumers and more than 90% of Fortune 500 companies. Business quality is high: ROE is 17.8%, TTM gross, operating and net margins are 62.6%, 28.2% and 21.9%, respectively, and 2Q 2026 revenue rose 28% year over year, or 15% excluding significant items; separate market data show revenue growth of 17.9% and earnings growth of 41.2% in the most recent quarter.
The investment grade as of this refresh is A- — high business quality. A-tier business, fair-tier historical valuation with 26.9% upside to $444.48 blended fair value.
Grade Change
In this research cycle, the investment grade for JPMorgan Chase & Co. moved from B to A-. A-tier business, fair-tier historical valuation with 26.9% upside to $444.48 blended fair value.
Key Metrics at a Glance
- Revenue growth: +17.9% year over year
- Net margin: 21.9%
- Fair value upside: +26.9% to our estimate of $444
Current price: $350.13
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. JPMorgan Chase & Co. remains in our covered universe with a high-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full JPM research →](/stocks/JPM)